Improving targeted therapies for osteoporosis
Optimizing bone surface targeting of therapeutic antibodies for osteoporosis
['FUNDING_R01'] · UNIVERSITY OF MICHIGAN AT ANN ARBOR · NIH-11029485
This study is looking at new ways to make osteoporosis treatments work better by delivering special antibodies right to the bones, which could help patients get safer and more effective care with fewer doses.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MICHIGAN AT ANN ARBOR (nih funded) |
| Locations | 1 site (ANN ARBOR, UNITED STATES) |
| Trial ID | NIH-11029485 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the effectiveness of osteoporosis treatments by developing methods to deliver therapeutic antibodies directly to bone surfaces. By increasing the local concentration of these therapies, the research aims to improve their safety and efficacy while reducing the frequency and dosage required for administration. The approach involves optimizing the pharmacokinetics and pharmacodynamics of a specific antibody in both healthy and osteoporotic animal models, with the goal of translating these findings into better treatment options for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with osteoporosis who may benefit from improved therapeutic options.
Not a fit: Patients who are not diagnosed with osteoporosis or those who have contraindications to antibody therapies may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective osteoporosis treatments that require less frequent dosing.
How similar studies have performed: Previous research has shown promise in enhancing the delivery of therapeutic antibodies, suggesting that this approach could lead to significant advancements in osteoporosis treatment.
Where this research is happening
ANN ARBOR, UNITED STATES
- UNIVERSITY OF MICHIGAN AT ANN ARBOR — ANN ARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GREINEDER, COLIN FRED — UNIVERSITY OF MICHIGAN AT ANN ARBOR
- Study coordinator: GREINEDER, COLIN FRED
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.